Human PTP sigma/PTPRS Antibody

Detection of Human PTP sigma /PTPRS by Western Blot.

Western blot shows lysates of SH-SY5Y human neuroblastoma cell line, CHP-100 human neuroblastoma cell line, and A431 human epithelial carcinoma cell line. PVDF membrane was probed with 1 µg/mL Goat Anti-Human PTP sigma/PTPRS Antigen Affinity-purified Polyclonal Antibody (Catalog # AF3430) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF109). For additional reference, recombinant human PTPR mu, PTPR kappa, LAR, PTPR sigma, PTPR delta, and PTPR beta (40 ng/lane) were included. A specific band for PTP sigma/PTPRS was detected at approximately 140 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.

PTP sigma /PTPRS in A431 Cell Line.

PTPs/PTPRS was detected in immersion fixed A431 human epithelial carcinoma cell line using Goat Anti-Human PTPs/PTPRS Antigen Affinity-purified Polyclonal Antibody (Catalog # AF3430) at 10 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Goat IgG Secondary Antibody (red; Catalog # NL001) and counterstained with DAPI(blue). Specific staining was localized to cytoplasm. View our protocol for Fluorescent ICC Staining of Cells on Coverslips.

Detection of PTPR sigma by Immunohistochemistry

GRIK1 localization in WT, FAT3, and PTP sigma mutant retinas. (A) Immunostaining for GRIK1 (magenta) in the OPL region of WT retinal sections. (B) Immunostaining for GRIK1 (magenta) in Fat3∆TM/∆TM retinal sections. (A′ and B′) Cone arrestin (ARR3) (white) labels the cone photoreceptor axonal endings in the OPL in A′ and B′. (C) Quantification of GRIK1 integrated intensity in the OPL. WT Controls: 1.00 ± 0.06 (n = 13 animals, 60 retinal regions); Fat3∆TM/∆TM: 0.56 ± 0.04 (n = 12 animals, 54 retinal regions). Each data point corresponds to a retinal region, color-coded by animal, nested two-tailed test. Error bar: SEM. (D) Immunostaining for GRIK1 (magenta) in the OPL region of WT retinal sections. (E) Immunostaining for GRIK1 (magenta) in the OPL region of Fat3∆ICD-GFP/∆ICD-GFP retinal sections. (D′ and E′) Cone arrestin (ARR3) (white) labels the cone photoreceptor endings in the OPL in D′ and E′. (F) Quantification of GRIK1 integrated intensity in the OPL. WT Controls: 1.00 ± 0.04 (n = 8 animals, 32 retinal regions); Fat3∆ICD/∆ICD: 0.75 ± 0.04 (n = 8 animals, 32 retinal regions). Each data point corresponds to a retinal region, color-coded by animal, nested two-tailed test. Error bar: SEM. (G) Immunostaining for GRIK1 (magenta) in the OPL region of WT retinal sections. (H) Immunostaining for GRIK1 (magenta) in Ptprs−/− retinal sections. (G′ and H′) Cone arrestin (ARR3) (white) labels the cone photoreceptor endings in the OPL in G′ and H′. (I) Quantification of GRIK1 integrated intensity in the OPL. WT Controls: 1.00 ± 0.06 (n = 6 animals, 30 retinal regions); Ptprs−/−: 0.66 ± 0.04 (n = 6 animals, 30 retinal regions). Each data point corresponds to a retinal region, color-coded by animal, nested two-tailed test. Error bar: SEM. Scale bars: 20 µm. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/39903280), licensed under a CC-BY license. Not internally tested by R&D Systems.